 WALTHAM, MA ACCESSWIRE September 30, 2019 EyeGate Pharmaceuticals, Inc. EYEG, EyeGate or the Company, a clinical-stage company focused on developing products for treating disorders of the eye, today announced that it has entered into a securities purchase agreement in connection with a private placement the Private Placement with an affiliate of Armistice Capital, LLC Armistice for aggregate gross proceeds of approximately 1.9 million. Steven J. Boyd, a director of EyeGate, is the Chief Investment Officer of Armistice. The Private Placement is expected to close on or about October 2, 2019, subject to the satisfaction of customary closing conditions. 